180847-24-9

Basic information

• Product Name: t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate
• Synonyms: 1-BOC-4-(3-bromophenoxymethyl)piperidine;t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate;tert-Butyl 4-((3-broMophenoxy)Methyl)piperidine-1-carboxylate
• CAS NO: 180847-24-9
• Molecular Formula: C₁₇H₂₄BrNO₃
• Molecular Weight: 370.28136
• Mol File: 180847-24-9.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate(180847-24-9)
• EPA Substance Registry System: t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate(180847-24-9)

Safety Data

• Hazardous Substances Data: 180847-24-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate is used as a key intermediate in the synthesis of new drugs. Its unique structure allows for the development of pharmaceuticals with novel mechanisms of action and therapeutic potential.
Used in Agrochemical Development:
In the agrochemical industry, t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate is utilized as a precursor for the creation of new pesticides and other agrochemicals. Its reactivity and structural features contribute to the design of effective and targeted products for agricultural use.
Used in Organic Synthesis:
t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate serves as a versatile building block in organic synthesis. Its bromophenoxy substituent and butyl ester group provide opportunities for further chemical modifications, enabling the synthesis of a wide range of organic compounds for various applications.
Researchers and chemists are actively studying the synthesis and properties of t-Butyl 4-((3-bromophenoxy)methyl)piperidine-1-carboxylate to explore its full potential in different fields. Its diverse applications make it a compound of significant interest in the scientific community.

Upstream product

• 591-20-8 3-Bromophenol 
• 158407-04-6 tert-butyl 4-(bromomethyl)piperidine-1-carboxylate 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 

Downstream Products

• 1310404-86-4 tert-butyl 4-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)methyl) piperidine-1-carboxylate 
• 1595289-72-7 N-(2-(3-(piperidin-4-ylmethoxy)phenyl)pyrimidin-4-yl)-1H-indazol-5-amine 
• 1595291-30-7 tert-butyl 5-(tert-butoxycarbonyl(2-(3-((1-(tert-butoxycarbonyl)piperidin-4-yl)methoxy)phenyl)pyrimidin-4-yl)amino)-1H-indazole-1-carboxylate 

Relevant articles and documents

Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine

Acetylcholinesterase (AChE) inhibitors are currently the first-line drugs approved by the FDA for the treatment of Alzheimer's disease (AD). However, a short effective-window limits their therapeutic benefits. Clinical studies have confirmed that the combination of AChE inhibitors and neuroprotective agents exhibits better anti-AD effects. We have previously reported that the dual AChE/GSK3β (Glycogen synthase kinase 3β) modulators have both neuroprotective effects and cognitive impairment-improvement effects. In this study, we characterized a new backbone of the AChE/GSK3β inhibitor 11c. It was identified as a highly potent AChE inhibitor and was found superior to donepezil, the first-line drug for the treatment of AD. In vivo studies confirmed that 11c significantly inhibited the activity of AChE in the brain but had little effect on the activity of AChE in the intestine. This advantage of 11c was expected to reduce the peripheral side effects caused by donepezil. Furthermore, biomarker studies have shown that 11c also improved the levels of acetylcholine and synaptophysin in the brain and exhibited neuroprotective effects. Preliminary in vivo and in vitro research results underline the exciting potential of compound 11c in the treatment of AD.

TREATMENT OF GVHD

The invention relates to treatment of graft versus host disease (GVHD) using compounds that inhibit ROCK2. In preferred aspects, the present invention provides methods for the treatment of GVHD, including chronic GVHD ( cGVHD) using compounds having the formulae l-XXV, as set forth herein.

TREATMENT OF OCULAR DISORDERS

The invention provides methods of treatment of ocular disorders, including ocular disease with an angiogenic component. In certain embodiments, the treatment comprises administration of a ROCK2 inhibitor and an angiogenesis inhibitor. In certain embodiments, the ROCK2 inhibitor is ROCK2 selective. In certain embodiments, the angiogenesis inhibitor is a VEGF antagonist, for example, and VEGFR2 antibody.

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).